Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) – ScienceOpen
11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Triple therapy (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) has been shown to improve symptoms and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. This real-world study compared exacerbation rates and healthcare resource utilization (HCRU) before and after initiation of FF/UMEC/VI in patients with COPD previously treated with inhaled corticosteroid (ICS)/long-acting β 2-agonist (LABA).

          Methods

          This retrospective cohort study included commercial and Medicare Advantage with Part D administrative claims data from September 01, 2016, to March 31, 2020, of patients diagnosed with COPD. The index date was the date of the first FF/UMEC/VI claim (September 2017–March 2019). The 12 months prior to index (baseline) were used to assess patient characteristics and outcomes; the 12 months following index (follow-up) were used to assess study outcomes. All patients had ≥ 30 consecutive days’ supply of any ICS/LABA dual therapy during the 12 months prior to FF/UMEC/VI initiation. Subgroup analyses included patients with ≥ 30 consecutive days’ supply of budesonide/formoterol (BUD/FORM) during baseline. Analyses of patients with ≥ 1 COPD exacerbation during baseline were reported as well.

          Results

          The overall population included 1449 patients (mean age 70.75 years; 54.18% female), of whom 540 were patients in the BUD/FORM subgroup. Significantly fewer patients experienced any exacerbation during follow-up versus baseline (overall population 53.49% vs 62.59%; p < 0.001; BUD/FORM subgroup 55.00% vs 62.41%; p = 0.004). Effects on exacerbation reduction were more pronounced among patients with ≥ 1 exacerbation during baseline. Lower COPD-related HCRU was observed during the follow-up compared with baseline for both the overall population and the BUD/FORM subgroup.

          Conclusion

          Patients with COPD treated with ICS/LABA during baseline, including patients specifically treated with BUD/FORM and those with a history of ≥ 1 exacerbation, had fewer COPD exacerbations and lower COPD-related HCRU after initiating FF/UMEC/VI.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s12325-023-02776-8.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

          With advances in the effectiveness of treatment and disease management, the contribution of chronic comorbid diseases (comorbidities) found within the Charlson comorbidity index to mortality is likely to have changed since development of the index in 1984. The authors reevaluated the Charlson index and reassigned weights to each condition by identifying and following patients to observe mortality within 1 year after hospital discharge. They applied the updated index and weights to hospital discharge data from 6 countries and tested for their ability to predict in-hospital mortality. Compared with the original Charlson weights, weights generated from the Calgary, Alberta, Canada, data (2004) were 0 for 5 comorbidities, decreased for 3 comorbidities, increased for 4 comorbidities, and did not change for 5 comorbidities. The C statistics for discriminating in-hospital mortality between the new score generated from the 12 comorbidities and the Charlson score were 0.825 (new) and 0.808 (old), respectively, in Australian data (2008), 0.828 and 0.825 in Canadian data (2008), 0.878 and 0.882 in French data (2004), 0.727 and 0.723 in Japanese data (2008), 0.831 and 0.836 in New Zealand data (2008), and 0.869 and 0.876 in Swiss data (2008). The updated index of 12 comorbidities showed good-to-excellent discrimination in predicting in-hospital mortality in data from 6 countries and may be more appropriate for use with more recent administrative data. © The Author 2011. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

                Bookmark

                Author and article information

                Contributors
                rosirene.x.paczkowski@gsk.com
                Journal
                Adv Ther
                Adv Ther
                Advances in Therapy
                Springer Healthcare (Cheshire )
                0741-238X
                1865-8652
                4 February 2024
                4 February 2024
                2024
                : 41
                : 3
                : 1245-1261
                Affiliations
                [1 ]Pulmonary and Critical Care Medicine, Johns Hopkins University, ( https://ror.org/00za53h95) Baltimore, MD USA
                [2 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, Value Evidence and Outcomes, R&D Global Medical, , GSK, ; Collegeville, PA 19426-0989 USA
                [3 ]Health Economics and Outcomes Research, Optum, ( https://ror.org/0370sjj75) Eden Prairie, MN USA
                [4 ]GRID grid.420846.c, Global Value Evidence and Outcomes, , GSK, ; Mississauga, ON Canada
                [5 ]Department of Health Research Methods, Evidence, and Impact, McMaster University, ( https://ror.org/02fa3aq29) Hamilton, ON Canada
                [6 ]GRID grid.430387.b, ISNI 0000 0004 1936 8796, Center for Health Outcomes, Policy and Economics, , Rutgers School of Public Health, ; Piscataway, NJ USA
                [7 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, US Medical Affairs, R&D Global Medical, , GSK, ; Durham, NC USA
                [8 ]GRID grid.430387.b, ISNI 0000 0004 1936 8796, Rutgers Institute for Translational Medicine and Science, ; New Brunswick, NJ USA
                Author information
                http://orcid.org/0009-0000-0624-1022
                http://orcid.org/0000-0002-5936-5579
                http://orcid.org/0000-0002-8114-6508
                http://orcid.org/0000-0002-8645-1990
                Article
                2776
                10.1007/s12325-023-02776-8
                10879256
                38310193
                62ec63f1-60c4-4747-aeef-b6f196f2adc8
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 28 September 2023
                : 18 December 2023
                Funding
                Funded by: GSK
                Categories
                Original Research
                Custom metadata
                © Springer Healthcare Ltd., part of Springer Nature 2024

                copd,dual therapy,exacerbations,ff/umec/vi,hcru,ics/laba,single-inhaler triple therapy

                Comments

                Comment on this article